title: Revisions to the requirements applicable to blood, blood components, and source plasma; confirmation in part and technical amendment. Food and Drug Administration, HHS.  Direct final rule; confirmation in part and technical amendment.
abstract: The Food and Drug Administration (FDA) is confirming in part the direct final rule issued in the Federal Register of August 19, 1999.  The direct final rule amends the biologics regulations by removing, revising, or updating specific regulations applicable to blood, blood components, and Source Plasma to be more consistent with current practices in the blood industry and to remove unnecessary or outdated requirements.  FDA is confirming the provisions for which no significant adverse comments were received.  The agency received significant adverse comments on certain provisions and is amending Title 21 Code of Federal Regulations to reinstate the former provisions.
mesh_terms: D001771:Blood Banks / Q000331:legislation & jurisprudence / Q000592:standards; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration